CRBN and Miyoshi myopathy: It provides the first evidence that RXR: PPAR heterodimer agonists are promising small molecule candidates that can upregulate CRBN expression and enhance the sensitivity of MM cells to IMiDs while maintaining glucose-lowering beneficial effects.